|
SLC38A9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.89979997978452E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.59477999999158E-05 |
| Normal-vs-Stage2 |
4.59960000087634E-08 |
| Normal-vs-Stage3 |
5.98399999551802E-08 |
| Normal-vs-Stage4 |
2.15100004474778E-09 |
| Stage1-vs-Stage2 |
1.494270E-02 |
| Stage1-vs-Stage3 |
8.900000E-02 |
| Stage1-vs-Stage4 |
3.942300E-03 |
| Stage2-vs-Stage3 |
3.817000E-01 |
| Stage2-vs-Stage4 |
4.824600E-01 |
| Stage3-vs-Stage4 |
9.849800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.16940000016719E-07 |
| Normal-vs-AfricanAmerican |
5.92669999965878E-07 |
| Normal-vs-Asian |
5.744200E-03 |
| Caucasian-vs-AfricanAmerican |
1.302220E-01 |
| Caucasian-vs-Asian |
2.302400E-01 |
| AfricanAmerican-vs-Asian |
1.718290E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.05210000045375E-07 |
| Normal-vs-Female |
5.59430000102168E-08 |
| Male-vs-Female |
3.503000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.64149999999963E-05 |
| Normal-vs-Age(41-60Yrs) |
1.19630000350313E-08 |
| Normal-vs-Age(61-80Yrs) |
2.34689999656368E-08 |
| Normal-vs-Age(81-100Yrs) |
1.139860E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.340300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.069900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.686000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.498200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.177000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.401800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.292400E-02 |
| Classical-VS-Follicular |
6.975200E-03 |
| Classical-VS-Other |
9.210400E-01 |
| Classical-VS-Normal |
3.60360000000171E-05 |
| Tall-VS-Follicular |
9.515800E-01 |
| Tall-VS-Other |
3.753600E-01 |
| Tall-VS-Normal |
2.31650000004358E-06 |
| Follicular-VS-Other |
4.602400E-01 |
| Follicular-VS-Normal |
7.63680000348543E-08 |
| Other-VS-Normal |
7.104000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.03549999685981E-08 |
| Normal-vs-N1 |
3.93600000003769E-06 |
| N0-vs-N1 |
9.992200E-01 |
|
|
